EMC Instytut Medyczny SA
Późna 60-309
2 studies enrolling now · 4 studies all time
What they study most
Moderately to Severely Active Crohns Disease, Moderately to Severely Active Ulcerative Colitis, Multiple Sclerosis
Studies at this site
- A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis — Recruiting now
- A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
- A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS) — Running, not enrolling
- A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS) — Running, not enrolling